Oncologists' recommendations for adjuvant therapy in hormone receptor-positive breast cancer patients of varying age and health status

Clinical Breast Cancer

Volumn 10, Issue 2, 2010, Pages 136-143

  Naeim, Arash ^a   Wong, F Lennie ^b   Pal, Sumanta ^b   Hurria, Arti ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitor; Endocrine therapy; Tamoxifen

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONE RECEPTOR; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; GROUPS BY AGE; HEALTH STATUS; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; QUESTIONNAIRE;

EID: 77950486283     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.018     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-1717 (Pubitemid 40719106)
2. Boccardo F, Rubagotti A, Guglielmini P, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006; 17(suppl 7):vii10-4.
3. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007; 369:559-570 (Pubitemid 46251559)
4. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9:45-53.
5. Goss PE, Ingle JN, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007; 25:2006-2011 (Pubitemid 46972784)
6. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366:455-462 (Pubitemid 41111693)
7. Thurlimann BJ, Keshaviah A, Mouridsen H, et al. BIG 1-98: randomized doubleblind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. J Clin Oncol 2005; 23(suppl):6s (abstract 511).
8. Crivellari D, Sun Z, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 2008; 26:1972-1979
9. Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7:633-643
10. Elkin EB, Hurria A, Mitra N, et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol 2006; 24:2757-2764 (Pubitemid 46630573)
11. Giordano SH, Duan Z, Kuo Y-F, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol 2006; 24:2750-2756 (Pubitemid 46630572)
12. Fargeot P, Bonneterre J, Roche H, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French Adjuvant Study Group 08 trial. J Clin Oncol 2004; 22:4674-4682 (Pubitemid 41185076)
13. Muss HB, Berry DL, Cirrincione C, et al. Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: results of CALGB/CTSU 49907. J Clin Oncol 2008; 26(suppl):8s (abstract 507).
14. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341:2061-2067 (Pubitemid 30035956)
15. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA 2005; 293:1073-1081 (Pubitemid 40300281)
16. Sandler AB, Hirsh V, Reck M, et al. Retrospective study of clinical and radiographic risk factors associated with early onset, severe pulmonary hemorrhage in bevacizumab-treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26(suppl):442s (abstract 8074).
17. Naeim A, Sawhney R, MacLean C, et al. Quality indicators for the care of breast cancer in vulnerable elders. J Am Geriatr Soc 2007; 55:S258-69. (Pubitemid 47512135)
18. Hurria A, Wong FL, Villaluna D, et al. Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers. J Clin Oncol 2008; 26:5386-5392
19. Hurria A, Wong FL, Pal S, et al. Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER2-positive breast cancer: a survey of oncologists. Oncologist 2009; 14:883-890
20. Colleoni M, Price KN, Castiglione-Gertsch M, et al. Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. Lancet 1999; 354:130-131 (Pubitemid 29313154)
21. Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol 2007; 25:3699-3704 (Pubitemid 47372610)
22. Sonpavde G, Hutson TE. Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007; 9:115-119 (Pubitemid 46332383)
23. Ozanne EM, Braithwaite D, Sepucha K, et al. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol 2009; 27:214-219
24. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25:1824-1831 (Pubitemid 46860271)
25. Arnold AM, Seymour L, Smylie M, et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007; 25:4278-4284 (Pubitemid 47548568)
26. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16:1582-1587 (Pubitemid 28175784)
27. Min LC, Reuben DB, MacLean CH, et al. Predictors of overall quality of care provided to vulnerable older people. J Am Geriatr Soc 2005; 53:1705-1711 (Pubitemid 43109933)
28. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000; 92:550-556 (Pubitemid 30212316)
29. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006; 24:3726-3734 (Pubitemid 46622311)